Hikma delivers exceptionally strong first half results with 20% revenue growth and 156% increase in adjusted EPS

All news

Hikma delivers exceptionally strong first half results with 20% revenue growth and 156% increase in adjusted EPS

Raising Group guidance to around 20% revenue growth for the full year, with a positive outlook for all businesses

London, 21 August 2013 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today reports its interim results for the six months ended 30 June 2013.

H1 2013 highlights


  • Group revenue increased by 19.9% to $638.3 million. Full year Group guidance raised to around 20% revenue growth
  • Group adjusted operating margin rose to 29.6%, up from 15.7%, reflecting significant improvement in Generics and Injectables margins
  • Profit attributable to shareholders increased by 82.1% to $73.6 million. On an adjusted basis, profit attributable to shareholders rose 157.2% to $121.2 million
  • Net cash flow from operating activities increased by $88.9 million to $136.0 million
  • Continued new product introductions across all countries and markets – launched 63 products and received 65 product approvals
  • Increase in the interim dividend to 7.0 cents per share, up from 6.0 cents in the first half of 2012, plus a special dividend of 3.0 cents per share that reflects the exceptional performance of the Generics business


  • Branded revenue grew 3.2%, or 8.7% in constant currency. The Branded business remains on track for around 11% full year revenue growth in constant currency
  • Branded adjusted operating profit grew by 10.6%, with adjusted operating margin of 22.6%


  • Global Injectables revenue grew 9.5%, with adjusted operating margin of 28.6%, driven by strong performances in the US and Europe
  • The Injectables business remains on track to deliver low double-digit revenue growth for the full year


  • Generics revenue increased by 136.6% to $132.0 million and full year Generics revenue guidance raised to $230 million, reflecting exceptionally strong doxycycline sales
  • Generics operating profit of $49.4 million, after non-recurring costs of $32.8 million

Said Darwazah, Chief Executive Officer of Hikma, said:

"The Group has made an excellent start to this year and all of our businesses are performing well.

In the MENA region, our strategic focus on higher value products and operational efficiencies is delivering improved profitability. Our global Injectables business continues to deliver good growth in revenue and a significant improvement in profitability. In particular, we are benefitting from strong demand for our products in the US and new product launches.

The Generics business is benefiting from exceptional sales of doxycycline and generated strong profitability in the first half of the year. This is enabling us to more than offset the impact of the ongoing remediation at our Eatontown facility and is providing excellent cash flow for the Group.

Overall, the Group is performing well and I am very pleased to be able to raise our Group guidance to around 20% revenue growth for the full year."

Group financial highlights

Summary P&L

$ million

H1 2013

H1 2012






Gross profit




Gross margin








Operating profit








Adjusted operating profit1,2




Adjusted operating margin
















Profit attributable to 









Adjusted profit attributable to 









Adjusted basic earnings per share (cents)








Dividend per share (cents)








Special dividend per 

share (cents)








Net cash flow from operating activities






Hikma Pharmaceuticals PLC


Susan Ringdal, VP Corporate Strategy and Investor Relations

+44 (0)20 7399 2760/

+44 7776 477050

Lucinda Henderson, Investor Relations Manager

+44 (0)20 7399 2765/

+44 7818 060211

FTI Consulting

Ben Atwell/ Julia Phillips/ Matthew Cole

+44 (0)20 7831 3113


About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.

A presentation for analysts and investors will be held today at 09:30 at FTI Consulting, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB. To join via conference call please dial: +44 (0) 203 139 4830 or 0808 237 0030 (UK toll free) and use participant PIN code: 93232833#. Alternatively you can listen live via our website at www.hikma.com. A recording of both the meeting and the call will be available on the Hikma website. Video interviews of Said Darwazah, CEO and Khalid Nabilsi, CFO are available at www.hikma.com . The contents of this website do not form part of this interim management report.

1Before the amortisation of intangible assets (excluding software) and exceptional items, as set out in note 4 to the condensed set of financial statements
2Adjusted profit and adjusted profit attributable to shareholders in H1 2012 have been re-classified to reflect the classification of certain exceptional items on a consistent basis with the treatment in H1 2013, as set out in note 4 to the condensed set of financial statements
3Earnings before interest, tax, depreciation and amortisation. EBITDA is stated before impairment charges and share of results from associated companies